Iter-4360dd15-0085-transcript
第 85 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 NEXT_FOCUS 原始人类试验 PMID 综述 引用链 主要终点 生存 健康寿命 失能自由生存"}) → call list_recent({"n":8})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0084-transcript", "tags": "iteration transcript", "modified": "20260424204726000", "preview": "!! 第 84 轮执行轨迹 → cal"}, {"title": "Iter-4360dd15-0083-transcript", "tags": "iteration transcript", "modified": "20260424204550000", "preview": "!! 第 83 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0084-reflection", "modified": "20260424204736000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424204736000", "tags": "pinned focus"}, {"title": "线索要尽快落到单个 PMID", "modified": "20260424204736000", "tags": "lesson citation-chain trial-audit endpoint-classification"}, {"title": "Iter-4360dd15-0084-transcript", "modified": "20260424204726000", "tags": "iteration transcript"}, {"title": "PMID 25540326 is immune-response endpoint, not longevity evidence", "modified": "20260424204718000", "tags": "4360dd15 fact classification clinical-trials longevity"}, {"title": "Iter-4360dd15-0083-reflection", "modified": "20260424204557000", "tags": "iteration reflection"}, {"title": "综述只能当入口，不能当证据", "modified": "20260424204557000", "tags": "lesson classification citation-chain trial-audit"}, {"title": "Iter-4360dd15-0083-transcript", "modified": "20260424204550000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "PMID 25540326 is immune-response endpoint, not longevity evidence", "modified": "20260424204718000"}, {"title": "PMID 27883166 is a pilot safety feasibility trial not direct longevity evidence", "modified": "20260424204543000"}, {"title": "PEARL trial is not direct longevity evidence", "modified": "20260424203525000"}, {"title": "Iter-4360dd15-0078-two-pmid-evidence-verification", "modified": "20260424203242000"}, {"title": "Iter-4360dd15-0077-unified-longevity-classification-four-pmids", "modified": "20260424203137000"}, {"title": "Iter-4360dd15-0075-abstract-field-extraction-two-pmids", "modified": "20260424202951000"}, {"title": "Iter-4360dd15-0072-review-exclusion-first-rule", "modified": "20260424202103000"}, {"title": "Iter-4360dd15-0071-minimal-audit-rules", "modified": "20260424201843000"}, {"title": "Iter-4360dd15-0069-standardized-audit-table-two-trials", "modified": "20260424201621000"}, {"title": "Iter-4360dd15-0068-abstract-endpoint-extraction", "modified": "20260424201407000"}, {"title": "Iter-4360dd15-0067-abstract-endpoints-aging-criteria", "modified": "20260424201141000"}, {"title": "Iter-4360dd15-0066-TierA-abstracts-and-endpoints-for-aging-criteria", "modified": "20260424200925000"}, {"title": "Iter-4360dd15-0065-minimal-relevance-decision-rules-for-retained-mtor-trials", "modified": "20260424200748000"}, {"title": "Iter-4360dd15-0064-relevance-tiering-10-pmids", "modified": "20260424200602000"}, {"title": "Iter-4360dd15-00
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"Iter-4360dd15-0061-candidate-audit-10-remaining-pmids"})
→ call read_note({"title":"Iter-4360dd15-0063-10-pmid-audit-table"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission 4360dd15 · Iter-0084）\n\n只追踪综述引用链中的 1 个未审计原始人类试验 PMID，并确认其主要终点是否直接涉及死亡、生存、健康寿命或失能自由生存。"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0061-candidate-audit-10-remaining-pmids", "tags": "4360dd15 knowledge fact classification clinical-trials", "text": "!! 第 61 轮：剩余 10 条候选 PMID 的研究类型审计完成\n\n本轮把上一轮留下的“剩余 10 条候选”逐条核对，并与已知的 4 条二次/延伸研究合并成 14 条完整清单。\n\n!! 结论\n- 保留 10 条：均可视为原始临床研究\n- 排除 4 条：标题明确指向 ancillary / follow-up / extension / postextension\n\n!! 保留 PMID\n- 33977284\n- 22367193\n- 29408453\n- 22115710\n- 35040506\n- 25525171\n- 24618547\n- 18037627\n- 27613521\n- 29992557\n\n!! 排除 PMID\n- 29806044\n- 31781682\n- 30564495\n- 34693520\n\n!! 最小可复现判定规则\n1. 标题若显式包含 ancillary / follow-up / extension / postextension，则排除为非原始研究。\n2. 标题若包含 randomized / placebo-controlled / phase / pilot / proof-of-concept / single-arm，不要自动排除；它们仍可能是原始临床研究。\n3. longitudinal analysis 若嵌在主试验题名中，只作为主试验附带分析，不单独构成排除理由。\n\n!! 复现备注\n- 先用记忆回忆上一轮留下的候选上下文\n- 再逐条对照题名进行结构化分类\n- 本轮已把“剩余 10 条候选”从噪声中清理为可审计的保留/排除结果"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0063-10-pmid-audit-table", "tags": "4360dd15 knowledge fact clinical-trials audit", "text": "!! 第 63 轮：10 条 PMID 可审计表\n\n本轮把上一轮已经用 PubMed 题名证据核实为“原始临床研究”的 10 条 PMID，整理为逐条可审计表，统一给出 PMID、题名、研究类型、保留/排除和理由。\n\n| PMID | 题名 | 研究类型 | 处理 | 理由 |\n|---:|---|---|---|---|\n| 33977284 | ''Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.'' | phase 2b/3 randomised trial | 保留 | 明确为随机临床试验，属于原始研究 |\n| 22367193 | ''A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.'' | single-dose controlled study | 保留 | 单次给药对照原始临床研究 |\n| 29408453 | ''A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects.'' | randomized controlled trial | 保留 | RCT，直接属于原始临床研究 |\n| 22115710 | ''A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema.'' | randomized dose-escalation study | 保留 | 剂量递增的原始临床试验 |\n| 35040506 | ''mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis.'' | randomized double-blind placebo-controlled futility trial + longitudinal analysis | 保留 | 主试验为原始临床试验；longitudinal analysis 为附带分析，不构成排除 |\n| 2552
→ call search_memory({"limit":10,"query":"33977284 22367193 29408453 22115710 35040506 25525171 24618547 18037627 27613521 29992557 primary endpoint"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0073-transcript", "tags": "iteration transcript", "modified": "20260424202419000", "preview": "!! 第 73 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 PMID 摘要 研究类型 年龄判据 主要终点 候选\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 NEXT_FOCUS PMID 候选 摘要 年龄判据 主要终点\"}) → call list_recent({\"n\":6}) → call list_by_tag({\"limit\":10,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424200117000\", \"preview\": \"!! 第 60 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 PMID 候选 摘要 年龄判据 主要终点 分类\"}) → call list_recent({\"n\":8}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0060-transcript\", \"t → call pubmed_search({"limit":5,"query":"33977284"})
【tool:pubmed_search】
{"ok": true, "query": "33977284", "results": [{"pmid": "33977284", "title": "Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.", "source": "Lancet Healthy Longev", "pubdate": "2021 May", "authors": ["Mannick JB", "Teo G", "Bernardo P", "Quinn D", "Russell K", "Klickstein L", "Marshall W", "Shergill S"], "url": "https://pubmed.ncbi.nlm.nih.gov/33977284/"}]}
→ call web_fetch({"max_chars":8000,"url":"https://pubmed.ncbi.nlm.nih.gov/33977284/"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/33977284/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call web_search({"limit":5,"query":"33977284 primary endpoint mTOR inhibitors improve immune function older adults phase 2b phase 3 randomised trials primary endpoint"})
→ call web_search({"limit":5,"query":"Mannick 33977284 primary endpoint immune function older adults mTOR phase 2b phase 3"})
→ call read_note({"title":"PMID 25540326 is immune-response endpoint, not longevity evidence"})
【tool:web_search】
{"ok": true, "query": "33977284 primary endpoint mTOR inhibitors improve immune function older adults phase 2b phase 3 randomised trials primary endpoint", "results": [{"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/", "snippet": "The mTOR inhibitor RTB101 10 mg once daily for 16 weeks was well tolerated in adults aged at least 65 years, increased expression of IFN-stimulated antiviral genes in peripheral blood, and decreased the incidence of laboratory-confirmed RTIs (the phase 2b primary endpoint ), but not the incidence of clinically symptomatic respiratory illness ..."}, {"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(21)00062-3/fulltext", "snippet": "The results of the phase 2b and phase 3 trials done in over 1500 adults aged at least 65 years confirm the results of the previous phase 2a trial that mTOR inhibition with RTB101 was well tolerated and consistently upregulated IFN-induced antiviral gene expression in older adults ."}, {"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://www.sciencedirect.com/science/article/pii/S2666756821000623", "snippet": "The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults , including interferon (IFN)-induced antiviral immunity that de
【tool:web_search】
{"ok": true, "query": "Mannick 33977284 primary endpoint immune function older adults mTOR phase 2b phase 3", "results": [{"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/", "snippet": "The results of the phase 2b and phase 3 trials done in over 1500 adults aged at least 65 years confirm the results of the previous phase 2a trial that mTOR inhibition with RTB101 was well tolerated and consistently upregulated IFN-induced antiviral gene expression in older adults ."}, {"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://www.sciencedirect.com/science/article/pii/S2666756821000623", "snippet": "The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults , including interferon (IFN)-induced antiviral immunity that declines with age. In a previous phase 2a trial, RTB101 (previously known as BEZ235), an oral mechanistic target of rapamycin ( mTOR ) inhibitor, was observed to increase IFN-induced antiviral gene expression and decrease the incidence .."}, {"title": "Targeting the biology of ageing with mTOR inhibitors to improve immune ...", "url": "https://europepmc.org/article/MED/33977284", "snippet": "The COVID-19 pandemic highlights the need for therapies that improve immune function in older adults , including interferon (IFN)-induced antiviral immunity that declines with age. In a previous ph
【tool:read_note】
{"ok": true, "title": "PMID 25540326 is immune-response endpoint, not longevity evidence", "tags": "4360dd15 fact classification clinical-trials longevity", "text": "!! 第 84 轮：对 PMID 25540326 的反证性审计\n\n- PMID：25540326\n- 题名：''mTOR inhibition improves immune function in the elderly.''\n- 公开摘要/网页抓取显示：研究对象是 elderly volunteers / elderly subjects；研究目的为评估 RAD001（rapalog）是否改善 //immune function// 与 //response to influenza vaccination//。\n- 公开 snippet 还给出主要终点的判据：需要在三种流感疫苗株中至少两种达到相对 placebo 的 1.2-fold titer increase 才算满足 primary endpoint（这说明终点是疫苗抗体反应，而不是生存或健康寿命）。\n\n!! 结论\n- 该试验是 //aging-related immunosenescence// 方向的短期生物标志物/免疫反应研究。\n- 它 //不是// 直接 longevity evidence，因为其主要终点不涉及死亡、生存、健康寿命或失能自由生存。\n- 这是一个高风险“伪长寿试验”样本：标题含 elderly / mTOR / aging language，容易误判，但审计后应排除。\n\n!! 证据来源\n- PubMed: https://pubmed.ncbi.nlm.nih.gov/25540326/\n- Europe PMC 摘要页: https://europepmc.org/abstract/med/25540326\n- Science/公开摘要 snippet: https://www.science.org/doi/10.1126/scitranslmed.3009892\n- web snippet 显示 primary endpoint 依赖 influenza antibody titers 的阈值，而非寿命终点。\n\n!! 复用规则\n- 若 trial 的主要终点是 vaccine response、antibody titer、immune marker、biomarker trajectory，即使对象是 elderly，也默认不算 direct longevity evidence。\n- 只有当 endpoint 明确是死亡、生存、健康寿命、失能自由生存，才进入长寿证据候选。"}
→ call web_fetch({"max_chars":12000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/"})
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Lancet Healthy Longev . 2021 May 6;2(5):e250–e262. doi: 10.1016/S2666-7568(21)00062-3 Search in PMC Search in PubMed View in NLM Catalog Add to search Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials Joan B Man
→ call write_note({"tags":["4360dd15","fact","classification","clinical-trials","longevity"],"text":"!! 第 85 轮：对 PMID 33977284 的端点审计\n\n- PMID：33977284\n- 题名：''Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.''\n- 证据源：PMC 全文 https://pmc.ncbi.nlm.nih.gov/articles/PMC8102040/\n\n!! 主要终点\n- phase 2b primary outcome：''the incidence )
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\PMID_33977284_is_RTI_incidence_endpoint_not_direct_longevity_evidence.tid", "title": "PMID 33977284 is RTI incidence endpoint, not direct longevity evidence"}
→ call write_note({"tags":["4360dd15","iteration","reflection"],"text":"!! 本轮进展\n- 成功把综述引用链中的一个未审计原始人类试验 PMID 落到具体 primary outcome：PMID 33977284。\n- 该试验虽然是原始随机临床试验，但主终点是 RTI / respiratory illness incidence，而非死亡、生存、健康寿命或失能自由生存。\n- 因此它应被排除出 direct longevity evidence。\n\n!! 关键证据链\n- PubMed 题名确认原始试验身份。\n- PMC 全文确认 phase 2b / phase 3 primary outcomes。\n- 与上一轮对 PMID 25540326 的免疫反应审计一致：mTOR/aging 语境下的试验常把短期免疫/感染结局伪装得很像长寿证)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Iter-4360dd15-0085-reflection.tid", "title": "Iter-4360dd15-0085-reflection"}
【assistant】
本轮已完成：把综述引用链中的 1 个未审计原始人类试验 PMID **33977284** 钉到主终点层面，并确认它的 primary outcome 是 **RTI / respiratory illness incidence**，不是死亡、生存、健康寿命或失能自由生存，所以**不构成 direct longevity evidence**。
我已把结论和反思写入长期记忆：
- `PMID 33977284 is RTI incidence endpoint, not direct longevity evidence`
- `Iter-4360dd15-0085-reflection`
< NEXT_FOCUS >从剩余候选 PMID 中挑 1 个题名最可能暗示 hard endpoint 的原始试验，核对其 primary outcome 是否直接指向死亡、生存、健康寿命或失能自由生存。< /NEXT_FOCUS >